Basic & Clinical Medicine ›› 2022, Vol. 42 ›› Issue (1): 114-119.

Previous Articles     Next Articles

Propofol inhibits proliferation of human endometrial cancer cell line RL95-2

  

  • Received:2020-11-16 Revised:2021-05-10 Online:2022-01-05 Published:2022-01-05

Abstract: Objective: To investigate the influence of propofol on the proliferation and apoptosis of endometrial cancer cells and the effect on mTOR/S6K1 signaling pathway. Methods: Human endometrial cancer cell line RL95-2 was divided into control group and propofol group. The control group was not intervened, and the propofol group was intervened with different concentrations of propofol. CCK-8 method was used to detect cell proliferation; clone formation assay was used to detect the ability of cell clone formation; flow cytometry was used to measure cell apoptosis; colorimetry was used to measure the activities of Caspase-3 and caspase-9; Western blot (WB) was used to detect the activation levels of protein kinase B (Akt), mammalian target of rapamycin (mTOR) and ribosomal protein S6 kinase 1 (S6K1). Results: Compared with those in the control group, the proliferation rate and colony forming ability of RL95-2 cells in propofol groups were significantly lower (P < 0.05), the apoptosis rate and the activities of Caspase-3 and caspase-9 were significantly higher (P < 0.05), the activation levels of Akt, mTOR and S6K1 were significantly lower (P < 0.05). Conclusion: Propofol may inhibit the proliferation and promote the apoptosis of endometrial cancer cells by regulating mTOR/S6K1 pathway.